The Coronavirus pandemic erupted in 2020 and new graduate registered nurses (RNs) found themselves caring for those with devastating illness as they were transitioning into nursing practice. The purpose of this study was to describe the experience of novice nurses working in acute care settings during a pandemic. This qualitative phenomenological study of novice nurses working in facilities providing acute care for COVID-19 patients was conducted in Phoenix, Arizona, USA. Purposive sampling identified 13 participants for interviews. Data were analyzed using thematic analysis. Eight themes emerged: Dealing with death, Which personal protective equipment (PPE) will keep us safe?, Caring for high acuity patients with limited training, Difficulties working short-staffed, Everything is not okay, Support from the healthcare team, Nursing school preparation for a pandemic, I would still choose nursing. Novice nurses felt challenged by the experience and were at times overwhelmed and struggling to cope. Support from peers and coping skills learned during nursing school helped them continue to work during a critical time. Data from this study suggest that some participants may have been experiencing symptoms of anxiety, depression, or post-traumatic stress disorder, and findings provide foundational insights for nursing education and psychological interventions to support the nursing workforce.
10 January 2024 in International Journal of Drug Policy
Experiences of discrimination, a notable psychosocial stressor, are considered an important risk factor for problematic opioid use. We examined whether pain severity, pain interference, anxiety, and depressive symptoms are pathways through which discrimination may be associated with increased prescription opioid misuse behaviors among individuals with chronic pain. A total of 234 participants who reported being prescribed opioids for chronic pain management were included from a parent longitudinal study collected from Amazon's MTurk. Study variables were collected at baseline and 12-month follow-up. Path analyses tested the hypothesized model, with socio-demographic variables and outcomes measured at baseline included as covariates. Mediated effects were examined using percentile bootstrap method. After controlling for socio-demographic covariates, pain severity, pain interference, anxiety, and depressive symptoms, baseline discrimination was significantly associated with greater prescription opioid misuse behaviors (p=.020) at 12 months. Baseline discrimination was also significantly associated with anxiety (p<.001) and depressive symptoms (p<.001) at 12 months. However, pain severity, pain interference, anxiety, and depressive symptoms were not significantly associated with prescription opioid misuse at 12 months. Mediation analyses indicated no significant effects. Discrimination may play an important role in prescription opioid misuse behaviors among individuals with chronic pain. Furthermore, discrimination is a risk factor contributing to elevated anxiety and depressive symptoms, with broad clinical implications for individuals coping with chronic pain. However, pain severity, pain interference, anxiety and depressive symptoms did not emerge as underlying mechanisms that link discrimination and prescription opioid misuse. Replication and extension in future studies are warranted.
Indigenous to West Africa, akuamma seed (Picralima nitida) is used in traditional medicine and demonstrates opioidergic activity. Little is known about its role in management of pain or other ailments among people in the United States. This study presents findings from a web-based survey conducted between December 2023 and July 2024. Summary statistics characterized individuals reporting lifetime akuamma seed use, including demographics, substance use history, pain severity, and motivations. Between-group comparisons were conducted for those with and without lifetime akuamma seed use. Among 369 participants, 28 (7.6%) reported lifetime akuamma seed use. Those with lifetime akuamma seed use were older (44.7 years, p = .04), females (64.3%, p = .004), or currently disabled (32.1%, p < .001). They reported less alcohol (p = .033), more kava (78.6%, p = .001) and Delta-8 THC (71.4%, p < .001) use; all had tried kratom. Those who had tried akuamma seed indicated greater pain severity and reported use for pain management and opioid substitution; 60.7% reported pain relief from akuamma seed. No participants met DSM-5 criteria for akuamma seed-related substance use disorder modified. Akuamma seed may be used in the United States alongside other unscheduled psychoactive substances, particularly, psychoactive botanical-derived products. Additional research is needed to evaluate safety, efficacy, and health outcomes associated with akuamma seed.